Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease

@inproceedings{Vichinsky2011LongtermSA,
  title={Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease},
  author={Elliott Vichinsky and Françoise Bernaudin and Gian Luca Forni and Ren{\'e}e Gardner and Kathryn Hassell and Matthew M Heeney and Baba P. D. Inusa and Abdullah Kutlar and Peter Lane and Liesl Mathias and John Porter and Cameron K. Tebbi and Felicia Wilson and Louis H. Griffel and Wei Deng and Vanessa Giannone and Thomas Elliot Coates},
  booktitle={British journal of haematology},
  year={2011}
}
To date, there is a lack of long-term safety and efficacy data for iron chelation therapy in transfusion-dependent patients with sickle cell disease (SCD). To evaluate the long-term safety and efficacy of deferasirox (a once-daily oral iron chelator), patients with SCD completing a 1-year, Phase II, randomized, deferoxamine (DFO)-controlled study entered a 4-year extension, continuing to receive deferasirox, or switching from DFO to deferasirox. Average actual deferasirox dose was 19·4 ± 6·3 mg… CONTINUE READING